Connect Biopharma’s (CNTB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Connect Biopharma (NASDAQ:CNTB) in a research report sent to investors on Thursday, MarketBeat Ratings reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

A number of other brokerages have also recently commented on CNTB. BTIG Research reduced their price target on shares of Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Oppenheimer lowered their price objective on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Wall Street Zen raised shares of Connect Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Piper Sandler began coverage on shares of Connect Biopharma in a report on Friday, June 26th. They set an “overweight” rating and a $7.00 target price on the stock. Finally, Weiss Ratings raised shares of Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.14.

Connect Biopharma Trading Down 1.2%

Shares of CNTB stock opened at $0.87 on Thursday. The business has a 50-day moving average price of $1.78 and a two-hundred day moving average price of $2.21. Connect Biopharma has a 12-month low of $0.85 and a 12-month high of $3.82. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm has a market cap of $54.78 million, a P/E ratio of -0.73 and a beta of -0.16.

Connect Biopharma (NASDAQ:CNTB) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. The firm had revenue of $2.75 million for the quarter, compared to the consensus estimate of $0.74 million. Equities analysts anticipate that Connect Biopharma will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Connect Biopharma

A number of large investors have recently bought and sold shares of CNTB. Bank of America Corp DE bought a new position in shares of Connect Biopharma in the first quarter worth approximately $41,000. Simplify Asset Management Inc. purchased a new position in shares of Connect Biopharma in the first quarter valued at about $135,000. Richmond Brothers Inc. bought a new position in shares of Connect Biopharma during the fourth quarter valued at about $489,000. Knott David M Jr raised its stake in shares of Connect Biopharma by 93.9% during the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after acquiring an additional 187,835 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Connect Biopharma during the first quarter worth about $1,945,000. 58.72% of the stock is owned by hedge funds and other institutional investors.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.